Clinical Trials, Policy, Programs and Therapy

A Bipartisan Bill Is Pledging $75 Million for Psychedelic Research in Military PTSD Treatment

Veriheal

JULY 18, 2023

The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE).

Treatment

Treatment Clinical Trials Research and Development Legislation

Veterans and Medical Cannabis: A Comprehensive Guide

MMJ Recs

MAY 9, 2024

There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.

Research and Development

Research and Development Therapy Clinical Trials Treatment

Harvard Is Launching America’s First Psychedelics Law and Policy Center

SpeedWeed

JULY 6, 2021

Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . This new program is being funded by private investors, including Matt Wullenweg, developer of WordPress, and philanthropist Tim Ferriss.

Policy

Policy Law Research and Development Therapy

Volteface: Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health

Cannabis Law Report

SEPTEMBER 10, 2021

Nick Milne PhD, Co-founder and CSO of Octarine said: “Our core ambition at Octarine is to advance psychedelic therapy across Europe and the world in a way that is consistent with sustainability principles while ensuring patient accessibility.

Research and Development

Research and Development Clinical Trials Therapy Environment

MAPS, in Coordination with Allies, Assists U.S. Sentencing Commission in Reaching Quorum

Cannabis Law Report

AUGUST 25, 2022

The MAPS Policy and Advocacy team coordinated a bipartisan coalition that met with U.S. Policy and Advocacy Director, MAPS. Its main focuses include establishing sentencing policies, advising Congress and the executive branch in developing criminal justice policy, and analyzing and distributing information on federal sentencing issues.

Research and Development

Research and Development Advocacy Clinical Trials Policy

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials

Clinical Trials Therapy Research and Development DEA

MAPS: “California Psychedelic Decriminalization Bill Slated for 2023 Reintroduction”

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization

Decriminalization Advocacy Research and Development Education

Press Release: Maya and National Psychedelics Association Announce Partnership to Support Psilocybin-Assisted Services in Oregon

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION. ABOUT MAYA.

Research and Development

Research and Development Therapy Safety Clinical Trials

Article: UC Berkeley Center for the Science of Psychedelics – Psychedelics and the Law

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law

Law Research and Development Therapy Treatment

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development

Research and Development DEA Clinical Trials Therapy

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Cannabis Law Report

NOVEMBER 15, 2021

PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. News release. FDA website. January 15, 2019.

Research and Development

Research and Development Therapy Clinical Trials Supply Chain

Ohio State University: New academic center focuses on psychedelic drug research and education

Cannabis Law Report

JUNE 19, 2022

The new center is designed to formalize a network of experts across the university based in a range of academic departments as well as existing centers focused on drug policy and substance misuse prevention and recovery. Davis and Slot predicted that as things stand, these therapies could be federally approved in three to five years. “If

Education

Education Research and Development Therapy Clinical Trials

Announcement: Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy

Therapy Pharmaceutical Clinical Trials Access

Position: Head of Global Regulatory Affairs MAPS PBC California Full-time

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Research and Development

Research and Development Clinical Trials Therapy Pharmaceutical

Weekly Legislative Roundup 1/18/19

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. Legislation is pending, House Bill 37, to permit physicians to recommend cannabis therapy to those struggling with opioid abuse or dependence. AK resident? HI resident? CO resident?

Legislation

Legislation Decriminalization Access Therapy

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

JULY 25, 2022

Conversation Tackles MAPS Research Methadology & Issues Of Abuse In Therapy. Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Psychedelics Today Podcast Interviews Rick Doblin.

Medicine

Medicine Therapy Research and Development Business

NORML 2019 Legislative Report

Cannabis Law Report

DECEMBER 30, 2019

Illinois and the US territory of Guam legalized adult-use cannabis and its retail sale, medical cannabis programs were enacted and expanded in several states, and 27 states considered legislation that would have legalized adult-use cannabis, a record-high. Historic House Judiciary Hearing on Marijuana Policy. Erik Altieri.

Legislation

Legislation Patients Access Banking

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development

Research and Development Medicine Treatment Pharmaceutical

Medical Cannabis Brief

A Bipartisan Bill Is Pledging $75 Million for Psychedelic Research in Military PTSD Treatment

Veterans and Medical Cannabis: A Comprehensive Guide

Trending Sources

Harvard Is Launching America’s First Psychedelics Law and Policy Center

Volteface: Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health

MAPS, in Coordination with Allies, Assists U.S. Sentencing Commission in Reaching Quorum

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

MAPS: “California Psychedelic Decriminalization Bill Slated for 2023 Reintroduction”

Press Release: Maya and National Psychedelics Association Announce Partnership to Support Psilocybin-Assisted Services in Oregon

Article: UC Berkeley Center for the Science of Psychedelics – Psychedelics and the Law

Senators Call For Report On State Of Psychedelic Research

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Ohio State University: New academic center focuses on psychedelic drug research and education

Announcement: Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer

Position: Head of Global Regulatory Affairs MAPS PBC California Full-time

Weekly Legislative Roundup 1/18/19

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

NORML 2019 Legislative Report

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Stay Connected